Soligenix Inc./$SNGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
- Ticker
- $SNGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14
- Headquarters
- Princeton, United States
- Website
- www.soligenix.com
Soligenix Inc. Metrics
BasicAdvanced
$7M
-
-$0.61
-
-
Price and volume
Market cap
$7M
52-week high
$1.70
52-week low
$0.28
Average daily volume
117K
Financial strength
Current ratio
2.996
Quick ratio
2.949
Long term debt to equity
0.024
Total debt to equity
0.044
Profitability
EBITDA (TTM)
-9.83
Effective tax rate (TTM)
5.43%
Management effectiveness
Return on assets (TTM)
-59.22%
Return on equity (TTM)
-127.42%
Valuation
Price to book
1.2
Price to tangible book (TTM)
1.2
Price to free cash flow (TTM)
-0.572
Free cash flow yield (TTM)
-174.85%
Free cash flow per share (TTM)
-0.562
Growth
Earnings per share change (TTM)
-82.14%
3-year earnings per share growth (CAGR)
-69.81%
10-year earnings per share growth (CAGR)
-48.55%
Soligenix Inc. Financial Performance
Revenues and expenses
Soligenix Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.